5 news items
Teva Engages In Settlement Talks Over Medicare Kickback Allegations
TEVA
18 Jun 24
is optimistic that the parties can reach a resolution, but additional time is needed to do so.”
This case is part of a broader investigation
Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
TEVA
1 Jun 24
in the University of Michigan School of Medicine's Department of Psychiatry and the study's lead investigator. "TD can impact all domains of daily functioning
Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia
TEVA
8 May 24
of Psychiatry at the Zucker School of Medicine, Hempstead, NY and SOLARIS study co-ordinating investigator. "Most patients with schizophrenia will experience
Teva's New Real-World Evidence Presented At The 2024 AAN Annual Meeting Confirms Effectiveness And Patient Satisfaction For HD Chorea With The 4-week Titration Kit For AUSTEDO Tablets
TEVA
16 Apr 24
consistently to their treatment plan, and achieve effective outcomes."The START study was a Phase 4 study investigating real-world treatment outcomes
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
TEVA
6 Apr 24
data include population pharmacokinetic (PopPK) modeling to investigate dosing conversion strategies for switching patients to a once-monthly or once
- Prev
- 1
- Next